MX2021012652A - Metodos para el tratamiento de sujetos con artritis psoriasica. - Google Patents

Metodos para el tratamiento de sujetos con artritis psoriasica.

Info

Publication number
MX2021012652A
MX2021012652A MX2021012652A MX2021012652A MX2021012652A MX 2021012652 A MX2021012652 A MX 2021012652A MX 2021012652 A MX2021012652 A MX 2021012652A MX 2021012652 A MX2021012652 A MX 2021012652A MX 2021012652 A MX2021012652 A MX 2021012652A
Authority
MX
Mexico
Prior art keywords
treatment
psoriatic arthritis
subjects
methods
hum13b8
Prior art date
Application number
MX2021012652A
Other languages
English (en)
Spanish (es)
Inventor
Kirti Wardhaman Ganorkar
Atul Mathuradas Raut
Anil Raghavan
Siu - Long Yao
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72837755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021012652(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MX2021012652A publication Critical patent/MX2021012652A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021012652A 2019-04-15 2020-04-15 Metodos para el tratamiento de sujetos con artritis psoriasica. MX2021012652A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Publications (1)

Publication Number Publication Date
MX2021012652A true MX2021012652A (es) 2022-01-24

Family

ID=72837755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012652A MX2021012652A (es) 2019-04-15 2020-04-15 Metodos para el tratamiento de sujetos con artritis psoriasica.

Country Status (16)

Country Link
US (1) US20220298233A1 (https=)
EP (1) EP3956357A4 (https=)
JP (2) JP7628962B2 (https=)
KR (1) KR20210140780A (https=)
CN (1) CN113825768A (https=)
AU (1) AU2020259375A1 (https=)
BR (1) BR112021020612A2 (https=)
CA (1) CA3143604A1 (https=)
IL (1) IL287213A (https=)
JO (1) JOP20210279A1 (https=)
MA (1) MA55729A (https=)
MX (1) MX2021012652A (https=)
MY (1) MY210310A (https=)
PH (1) PH12021552536A1 (https=)
SG (1) SG11202111056YA (https=)
WO (1) WO2020212874A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024323792A1 (en) * 2023-08-11 2026-03-12 Innovent Biologics (Suzhou) Co., Ltd. Method for treating plaque psoriasis wherein subject previously receiving biologic therapy for plaque psoriasis switches to using anti-il23p19 antibody
AU2024338774A1 (en) * 2023-09-07 2026-03-26 Innovent Biologics (Suzhou) Co., Ltd. Method for treating moderate and severe psoriasis using recombinant anti-il-23p19 antibody
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
EP2007426A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
AR065420A1 (es) * 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Also Published As

Publication number Publication date
MY210310A (en) 2025-09-10
JP2022529266A (ja) 2022-06-20
US20220298233A1 (en) 2022-09-22
AU2020259375A1 (en) 2021-10-28
EP3956357A1 (en) 2022-02-23
BR112021020612A2 (pt) 2021-12-28
JP2025069284A (ja) 2025-04-30
KR20210140780A (ko) 2021-11-23
PH12021552536A1 (en) 2022-07-04
CN113825768A (zh) 2021-12-21
MA55729A (fr) 2022-02-23
JP7628962B2 (ja) 2025-02-12
JOP20210279A1 (ar) 2021-10-14
EP3956357A4 (en) 2023-01-04
SG11202111056YA (en) 2021-11-29
WO2020212874A1 (en) 2020-10-22
IL287213A (en) 2021-12-01
CA3143604A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
JOP20190292A1 (ar) استخدام الأجسام المضادة لربط il-1? في علاج السرطان
MX2024001803A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
CL2020003026A1 (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CO2019002370A2 (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo
MX2018013520A (es) Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
MX2021015309A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
MX2021012652A (es) Metodos para el tratamiento de sujetos con artritis psoriasica.
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
ECSP21022299A (es) Anticuerpos de anti-cd33 y métodos para usarlos
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
PY2018606A (es) Anticuerpo monoclonal que se une específicamente a GITR
MX392703B (es) Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada.
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
DOP2022000129A (es) Anticuerpos contra la integrina alfa 11 beta 1
MX375897B (es) Novedoso anticuerpo anti-presepsina.
BR112021025060A2 (pt) Dosagem modificada de tocilizumab subcutâneo para artrite reumatóide
MX2021002647A (es) Metodos de tratamiento de la psoriasis.
EA202190228A1 (ru) Модификация связывающих молекул для минимизации уже существующих взаимодействий
MX2021009690A (es) Anticuerpo anti-bag2 y metodos de tratamiento del cancer.